The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL. Al-Sawaf O, Furstenau M, Giza A, Robrecht S, et al. Blood 2025;146:2406-2416.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Al-Sawaf O, Furstenau M, Giza A, Robrecht S, et al. The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL. Blood 2025;146:2406-2416.
PMID: 40864973